Apricus Biosciences CEO, Dr. Bassam Damaj, to Present at Biotech Showcase(TM) 2012 in San Francisco
Apricus Biosciences, Inc.
04.01.2012 15:49
---------------------------------------------------------------------------
SAN DIEGO, 2012-01-04 15:49 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Dr. Bassam Damaj, Chairman,
President and Chief Executive Officer, will present a company overview at
Biotech Showcase(tm) 2012, being held at the Park Wyndham Hotel in San Francisco,
California, from January 9 to January 11, 2012. Apricus Biosciences'
presentation will be held on Monday, January 9, 2012 at 2:30pm Pacific Time.
About the Biotech Showcase(tm)
Now in its fourth year, Biotech Showcase(tm) will feature corporate presentations
by 200+ innovative life science companies to an audience of public and private
investors, business development executives and professional advisors who are
interested in investment opportunities and collaboration. The showcase takes
place during the week of one of the most important healthcare investor
conferences which annually attracts thousands of healthcare and life science
business executives to San Francisco in a venue located close to the center of
action. To maximize efficiency, all showcase participants can schedule
one-on-one meetings through the organizer's online system, partneringONE(r).
Public and private investors are always invited to attend the showcase on a
complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life
Science Advisors and EBD Group, two organizations that have a long and
successful history building programs that meet the needs of the life sciences
industry. Visit our website for more information: www.ebdgroup.com/bts.
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical
company, with commercial products and a broad pipeline across numerous
therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial
products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc.
subsidiaries and through out-licensing in certain territories of its product
pipeline and NexACT(r) technology. Apricus Bio's current pipeline includes
Vitaros(r), approved in Canada for the treatment of erectile dysfunction, Totect(r)
the only drug approved in the U.S. for the treatment of anthracycline
extravasation, as well as compounds in development from pre-clinical through
pre-registration, currently focused on Sexual Dysfunction, Oncology,
Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer
Healthcare.
The Company also expects to develop and/or acquire and then bring to market
additional pharmaceutical products in areas of care that will benefit patient
needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to receive issued patents on its
NexACT(r) technology and products, develop such patented technology into product
candidates, have its Rx Division products and product candidates such as
Vitaros(r) approved by relevant regulatory authorities and its Consumer
Healthcare Division products either approved or cleared by relevant regulatory
authorities or be in compliance with appropriate regulatory requirements, to
successfully manufacture and commercialize such Rx Division products as Totect(r)
for the treatment of anthracycline extravasation and Vitaros(r) in the U.S.,
Canada, and in other countries along with its Consumer Healthcare Division
products and product candidates and to achieve its other development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development & Investor Relations, Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
04.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Apricus Biosciences, Inc.
04.01.2012 15:49
---------------------------------------------------------------------------
SAN DIEGO, 2012-01-04 15:49 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Dr. Bassam Damaj, Chairman,
President and Chief Executive Officer, will present a company overview at
Biotech Showcase(tm) 2012, being held at the Park Wyndham Hotel in San Francisco,
California, from January 9 to January 11, 2012. Apricus Biosciences'
presentation will be held on Monday, January 9, 2012 at 2:30pm Pacific Time.
About the Biotech Showcase(tm)
Now in its fourth year, Biotech Showcase(tm) will feature corporate presentations
by 200+ innovative life science companies to an audience of public and private
investors, business development executives and professional advisors who are
interested in investment opportunities and collaboration. The showcase takes
place during the week of one of the most important healthcare investor
conferences which annually attracts thousands of healthcare and life science
business executives to San Francisco in a venue located close to the center of
action. To maximize efficiency, all showcase participants can schedule
one-on-one meetings through the organizer's online system, partneringONE(r).
Public and private investors are always invited to attend the showcase on a
complimentary basis. Biotech Showcase was co-founded by Demy-Colton Life
Science Advisors and EBD Group, two organizations that have a long and
successful history building programs that meet the needs of the life sciences
industry. Visit our website for more information: www.ebdgroup.com/bts.
About Apricus Biosciences, Inc.
Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical
company, with commercial products and a broad pipeline across numerous
therapeutic classes.
Revenues and growth are driven from the sales of the Company's commercial
products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc.
subsidiaries and through out-licensing in certain territories of its product
pipeline and NexACT(r) technology. Apricus Bio's current pipeline includes
Vitaros(r), approved in Canada for the treatment of erectile dysfunction, Totect(r)
the only drug approved in the U.S. for the treatment of anthracycline
extravasation, as well as compounds in development from pre-clinical through
pre-registration, currently focused on Sexual Dysfunction, Oncology,
Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer
Healthcare.
The Company also expects to develop and/or acquire and then bring to market
additional pharmaceutical products in areas of care that will benefit patient
needs worldwide.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio and
http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to receive issued patents on its
NexACT(r) technology and products, develop such patented technology into product
candidates, have its Rx Division products and product candidates such as
Vitaros(r) approved by relevant regulatory authorities and its Consumer
Healthcare Division products either approved or cleared by relevant regulatory
authorities or be in compliance with appropriate regulatory requirements, to
successfully manufacture and commercialize such Rx Division products as Totect(r)
for the treatment of anthracycline extravasation and Vitaros(r) in the U.S.,
Canada, and in other countries along with its Consumer Healthcare Division
products and product candidates and to achieve its other development,
commercialization and financial goals. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein. Readers are
urged to read the risk factors set forth in the Company's most recent annual
report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from the SEC's
website or without charge from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Corporate Development & Investor Relations, Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
04.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------